- TOUJEOTMis a once daily, long-acting basal insulin used to control blood sugar in adults with type 1 and type 2 diabetes
- Diabetes continues to be one of India’s biggest health challenges: 73 mnpeople in the country, 1 in every 12 people in Maharashtrawith diabetes
Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study: Ranjit Mohan Anjana et al, Lancet Diabetes
New Delhi, February 13, 2018: Sanofi Indiacontinues to deliver breakthrough medicines for the management of diabetes with the launch of its new product – Toujeo™,the next generation basal insulin. Toujeo™ is a once-daily,long-actingbasal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.
Low blood sugar, or hypoglycemia is a constant fear amongst people on insulin. Toujeo™ has demonstrated that it effectively lowers blood glucose, while minimizing the risk of hypoglycemia. It works by slowly releasing small amounts of insulin to provide continuous glucose-lowering activity that lasts beyond 24 hours. With its stable and flat/peak-less action profile, Toujeo™ reduces glycemic variability, i.e. the daily highs and lows that people with diabetes on insulin may experience.
Corporate Comm India(CCI Newswire)
